Up and running again

A Boston Scientific therapy helped Esther overcome cancer pain.

Read her story

Featured stories
Jul 29, 2026
Interested in our Q2 2026 earnings?

Get some key highlights of our performance this quarter.

The eCoin System stimulates the tibial nerve to help address urge urinary incontinence symptoms.
Jul 1, 2026
Four things to know about our acquisition of Valencia Technologies

Learn how the acquisition expands treatment options for overactive bladder and urge urinary incontinence.

Photo of a lemon, illustrating that a prostate enlarges over the course of a man’s life, sometimes becoming lemon-sized, which can result in BPH.
Jun 17, 2026
What is an enlarged prostate (BPH) and how is it treated?

This common urinary condition affects about half of men by age 60. Learn about BPH's causes, symptoms and treatments.

Read more stories

Press releases
Jul 29, 2026
Boston Scientific announces results for second quarter 2026

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and...

May 19, 2026
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease

May 18, 2026
Boston Scientific enters into $2 billion accelerated share repurchase agreement

Accelerated share repurchase agreement is part of Company's previously announced $5 billion share repurchase authorization.

Read more press releases

In the news
Mar 29, 2026
Data supports Boston Scientific Watchman FLX™ in stroke reduction
MassDevice
The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.
Mar 28, 2026
HI-PEITHO kicks off ‘golden era’ in pulmonary embolism
MedPage Today
Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.
Jan 26, 2026
Hospitals are embracing pulsed field ablation. Here’s why
Modern Healthcare
Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.
Jan 15, 2026
Lab profile: Boston Scientific’s Arbor Lakes campus was built to be reconfigurable
R&D World
Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Read more news

2025 Impact Reporting

Advancing science for more innovative care, empowered people and a more sustainable future.

Learn about our impact

News alerts

Sign up to receive our press releases via email

Media contacts

Business and enterprise contacts for journalists

Media resources

Imagery and other resources

Top